Clinical Trial Update: Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sitaxsentan dosing in patients undergoing cardiac surgery, including CABG or cardiac valve replacement; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Surgery Complications
• Heart Disease
• Pulmonary Arterial Hypertension

Drugs mentioned

• Sitaxsentan (sitaxsentan)

Snippet

Sponsor: Pfizer | Conditions: Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement | Phase 2 | Status: COMPLETED | Results posted: 2022-09-08